Polyrizon Ltd.
No enriched coverage for $PLRZ in the last 7 days.
No SEC Form 4 filings for $PLRZ in the last 30 days.
See all $PLRZ insider activity →Polyrizon Ltd. (PLRZ) completed contracting with U.S. clinical sites for its NASARIX Allergy Blocker (PL-14) trial, advancing into first-in-human study execution. The trial will evaluate efficacy, safety, and tolerability in 120 patients with seasonal allergic rhinitis. PLRZ stock traded between $2.88 and $18.20 over the past year, closing at $14.36 on Tuesday.
Polyrizon Ltd. (NASDAQ: PLRZ) said its NASARIX™ Allergy Blocker intranasal hydrogel nasal spray passed biocompatibility and biological safety tests, meeting predetermined acceptance criteria. The program covered endpoints including cytotoxicity, sensitization, irritation, pyrogenicity, and acute systemic toxicity, with long-term systemic toxicity assessed via ISO 10993-17 risk review.
Polyrizon Ltd. (Nasdaq: PLRZ) said its NASARIX™ intranasal allergy-blocker biocompatibility program completed successfully, with required biological safety tests meeting preset acceptance criteria. The program covered cytotoxicity, sensitization, irritation, pyrogenicity, and acute systemic toxicity, plus long-term systemic toxicity risk assessment under ISO 10993. The company said results support advancement toward first-in-human clinical trials.
Recent PLRZ coverage spans financial news, technology and market movers.
The site‑contracting milestone enables the start of patient enrollment for the FIH trial, reducing execution risk and potentially supporting near‑term share price upside.
Positive completion of required biocompatibility endpoints reduces regulatory risk for NASARIX’s device safety package and can support progression toward clinical/regulatory steps.
Successful completion of the NASARIX biocompatibility program strengthens the non-clinical safety package supporting its regulatory/clinical pathway.
Positive biocompatibility test completion is a near-term de-risking milestone for NASARIX’s regulatory/clinical pathway.
Patent publication can improve IP defensibility and optionality for future partnerships/therapeutic programs.
AlphAI scores every news story that mentions PLRZ with an AI model for sentiment and relevance, and aggregates insider trades from Polyrizon Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Polyrizon Ltd. (PLRZ) completed contracting with U.S. clinical sites for its NASARIX Allergy Blocker (PL-14) trial, advancing into first-in-human study execution. The trial will evaluate efficacy, safety, and tolerability in 120 patients with seasonal allergic rhinitis. PLRZ stock traded between $2.88 and $18.20 over the past year, closing at $14.36 on Tuesday.
1 min readPolyrizon Ltd. (NASDAQ: PLRZ) said its NASARIX™ Allergy Blocker intranasal hydrogel nasal spray passed biocompatibility and biological safety tests, meeting predetermined acceptance criteria. The program covered endpoints including cytotoxicity, sensitization, irritation, pyrogenicity, and acute systemic toxicity, with long-term systemic toxicity assessed via ISO 10993-17 risk review.
2 min readPolyrizon Ltd. (Nasdaq: PLRZ) said its NASARIX™ intranasal allergy-blocker biocompatibility program completed successfully, with required biological safety tests meeting preset acceptance criteria. The program covered cytotoxicity, sensitization, irritation, pyrogenicity, and acute systemic toxicity, plus long-term systemic toxicity risk assessment under ISO 10993. The company said results support advancement toward first-in-human clinical trials.
3 min readPolyrizon Ltd. (NASDAQ:PLRZ) shares rose about 10% after the company reported successful biocompatibility test results for its NASARIX Allergy Blocker nasal spray. Polyrizon said required biological safety endpoints met predetermined acceptance criteria under ISO 10993 and related FDA/EU guidance, supporting progress toward clinical and regulatory steps.
3 min readuniQure (QURE) surged 78% after the FDA said the 3-year Phase I/II analysis for AMT-130 in Huntington’s could serve as primary evidence for an accelerated BLA; QURE plans to file in Q3 2026. Elicio (ELTX) rose 71% on Phase 2 AMPLIFY-7P responses. Lunai (LNAI) gained 40% on CEO updates; other biotech movers included CLPT, PLRZ and FTH.
5 min readPolyrizon Ltd. director Carmel Liron reported an open-market sale of 100 Ordinary Shares at $11.00 per share on March 30, 2026. Following this transaction, Liron directly holds 4,069 ordinary shares, which include 1,463 unrestricted shares and 2,606 restricted ordinary shares that vest quarterly conditional on continued service. The filing also clarifies that no derivative securities were involved in this transaction.
2 min readPolyrizon Ltd.'s Chief Technology Officer, Tidhar Turgeman, has sold 2,917 Ordinary Shares at $10.90 per share in an open-market transaction, as reported in a recent Form 4 filing. Following this sale, Turgeman directly holds 17,518 Ordinary Shares, which include 18 restricted shares vesting monthly and 17,500 restricted shares vesting quarterly, contingent on his continued employment. The transaction is categorized as a neutral filing impact with a negative sentiment, reflecting a routine insider sale rather than a grant or option exercise.
2 min readPolyrizon (NASDAQ:PLRZ) is an unprofitable biotech company currently burning cash, with a cash runway of about 2.5 years based on its US$11m cash reserves and US$4.5m annual burn rate. While its runway is considered reasonable, its cash burn increased by 295% in the last year, which could lead to significant shareholder dilution if it needs to raise more capital. Despite the high burn rate, the company's cash runway provides some comfort to investors.
2 min readIn-Vitro Data Confirms Strong Protection Against H1N1 Influenza via Physical Barrier Mechanism ...
2 min readRa'anana, Israel, Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Polyrizon Ltd. ( Nasdaq: PLRZ ) ( "Polyrizon" or the "Company" ) , a biotechnology company developing intranasal products based on its proprietary Capture & Contain ( C&C ) platform, today announced encouraging results from a recent ...
2 min read
